Fox Chase Cancer Center News

PHILADELPHIA (November 17, 2020)—Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel, also known as Tecartus, the first cell-based gene therapy approved by the Food and Drug Administration (FDA).

PHILADELPHIA (November 16, 2020)—Two leading researchers from Fox Chase Cancer Center are co-authors of the fifth edition of Principles of Virology, the leading virology textbook for undergraduate and graduate students studying how viruses reproduce and cause disease.

PHILADELPHIA (November 13, 2020) – In a recently published paper, researchers at Fox Chase Cancer Center unveiled data that suggested possible new targets for the treatment of T-acute leukemia/lymphoma (T-ALL).

PHILADELPHIA (November 5, 2020) – Researchers at Fox Chase Cancer Center have harnessed the power of the Nobel Prize-winning CRISPR/Cas9 technology to identify cellular factors involved in resistance to sunitinib by clear cell renal cell carcinoma.

PHILADELPHIA (November 4, 2020)—Fox Chase Cancer Center has become the first cancer center in the Northeast to feature a new tumor marker technology that has been described as the next generation of surgical navigation, one that will make breast excisional biopsies and breast-conserving surgeries more precise.

PHILADELPHIA (October 30, 2020) – In a study released online today, researchers at Fox Chase Cancer Center have identified a new biomarker and potential novel treatment target for pancreatic ductal adenocarcinoma (PDAC) that could help starve cancer cells and allow the immune system to attack the tumor.

PHILADELPHIA (October 30, 2020) – Pathogenic variants in DNA damage response and repair (DDRR) genes have been identified in patients with early onset renal cancer, according to a recent study by researchers at Fox Chase Cancer Center.

PHILADELPHIA (October 29, 2020)—Researchers from Fox Chase Cancer Center have presented new data indicating that several factors, the most significant one being pain, are significantly associated with a reduction in the number of working days per week in patients who attempt to work while receiving radiation treatment for head and neck cancer (HNC).